title: Exclusive characteristics of graft survival and risk factors in recipients with immunoglobulin A nephropathy: a retrospective analysis of registry data.
abstract: BACKGROUND
  Some studies have claimed that patients with immunoglobulin A (IgA) nephropathy have better graft survival than other renal graft recipients, whereas others have rejected this statement. We have addressed this paradox in the present study.
  
  
  METHODS
  In all, 1,207 patients with IgA nephropathy who received a primary cadaveric renal graft from 1990 to 2002 were identified in the Eurotransplant database. For comparison, we analyzed 7,935 patients with nonglomerular diseases. Death-censored graft survival was calculated using Kaplan Meier estimates and a multivariable Cox regression analysis was used for risk calculations.
  
  
  RESULTS
  Death-censored graft survival was superior in patients with IgA nephropathy in the first period after transplantation. After 3 years posttransplant, however, there was an accelerated decline in graft survival in recipients with IgA nephropathy. The fully adjusted risk of graft loss in the first year was increased by 40% in the control group compared to IgA nephropathy (hazard ratio [HR] 1.40, 95% CI 1.12-1.75), whereas the risk was significantly lower in the control group after the first year posttransplant (HR 0.75, 95% CI 0.63-0.88). Cold ischemia time, immunization and HLA-DR mismatch were risk factors for graft loss in the control group but not for IgA nephropathy, whereas HLA-AB mismatch was an independent risk factor, exclusively for the IgA nephropathy group.
  
  
  CONCLUSIONS
  Recipients with IgA nephropathy have better 1-year graft survival, presumably due to favorable immunological behavior. This benefit was however abolished in the long-term by increased graft loss with time. Studies are needed to explain the difference in graft survival and the reason why different risk factors are involved in graft failure.
authors.affiliation: Division of Nephrology, Landspitali University Hospital, Reykjavik, Iceland. mband@landspitali.is
authors.forename: Margret B
authors.initials: MB
authors.lastname: Andresdottir
authors.forename: Geert W
authors.initials: GW
authors.lastname: Haasnoot
authors.forename: Ilias I N
authors.initials: II
authors.lastname: Doxiadis
authors.forename: Guido G
authors.initials: GG
authors.lastname: Persijn
authors.forename: Frans H J
authors.initials: FH
authors.lastname: Claas
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D005922:Glomerulonephritis, IGA / Q000276:immunology / Q000401:mortality / Q000601:surgery*; D006084:Graft Rejection / Q000453:epidemiology* / Q000401:mortality; D006085:Graft Survival; D006801:Humans; D007070:Immunoglobulin A / Q000276:immunology; D016030:Kidney Transplantation / Q000401:mortality; D008297:Male; D008875:Middle Aged; D012042:Registries; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D007070:Immunoglobulin A